Table 1.
COVID-19 IMPACT study population characteristics per chronic disease status.
| Disease status known | Disease status imputed (N = 512) | Overall (N = 5411) | |||
|---|---|---|---|---|---|
| No chronic disease (N = 3383) | Chronic disease (N = 1516) | P value | |||
| Age [year] | 53.2 [24.0, 78.0] | 58.7 [24.0, 78.1] | < 0.001 | 55.9 [23.1, 78.0] | 55.0 [23.1, 78.1] |
| Sex, Female | 1889 (55.8%) | 766 (50.5%) | < 0.001 | 279 (54.5%) | 2934 (54.2%) |
| BMI [kg/m2]* | 24.2 [15.6, 30.0] | 28.6 [16.1, 56.7] | < 0.001 | – | 25.6 [15.6, 56.7] |
| Urbanicity of residential area | 0.558 | ||||
| < 1000 addresses/km2 | 1501 (44.4%) | 693 (45.7%) | 252 (49.2%) | 2446 (45.2%) | |
| > 1000 addresses/km2 | 1801 (53.2%) | 800 (52.8%) | 260 (50.8%) | 2861 (52.9%) | |
| Asthma or COPD | – | 540 (35.6%) | – | 540 (10.0%/11.0%)† | |
| Diabetes | – | 215 (14.2%) | – | 215 (3.9%/4.4%)† | |
| Cardiovascular disease | – | 532 (35.1%) | – | 532 (9.8%/10.9%)† | |
| Obese (BMI > 30) | – | 645 (42.5%) | – | 645 (11.9%/13.2%)† | |
| COVID-19 before or during study | 592 (17.5%) | 270 (17.8%) | 0.823 | 56 (10.9%) | 918 (17.0%) |
| Cohort | < 0.001 | ||||
| AMIGO | 2016 (59.6%) | 1082 (71.4%) | 285 (55.7%) | 3383 (62.5%) | |
| PIAMA | 632 (18.7%) | 140 (9.2%) | 76 (14.8%) | 848 (15.7%) | |
| VGO | 735 (21.7%) | 294 (19.4%) | 151 (29.5%) | 1180 (21.8%) | |
Data are presented as mean [range] or n (%). P-values: Wilcoxon or chi2 test comparing known disease status groups. Disease status was imputed if baseline age, sex and urbanicity were available. *BMI = mass(kg)/(height (m))2. †Percentages calculated for the overall total, and participants with known disease status (N = 5411/N = 4899).